Revenues at Pharmaceutical Product Development (Nasdaq: PPDI) grew more than 7 percent from a year ago in the third quarter, the life science services company reported Wednesday.
Revenues rose to $365.4 million for the quarter.
The profit of 32 cents per share matched the 2009 quarterly total.
“Gross authorizations continued to be strong, and operating margin expanded significantly on a sequential basis due to improved performance in emerging markets and our focus on overall company spending,” said PPD Chief Executive Officer David Grange in a statement.
For the full report,
Get the latest news alerts: at Twitter.
